Bisphosphonates induce the osteogenic gene expression in co-cultured human endothelial and mesenchymal stem cells

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 1, 2014, Pages 27-37

  Ribeiro, Viviana ^a,b   Garcia, Mónica ^b   Oliveira, Raquel ^a,b   Gomes, Pedro S ^b   Colaço, Bruno ^a   Fernandes, Maria Helena ^b  

^a UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^b U Porto   (Portugal)

Author keywords

Alendronate; Co cultured cells; Endothelial gene expression; Human dermal microvascular endothelial cells (HDMEC); Human mesenchymal stem cells (HMSC); Osteogenic gene expression; Zoledronate

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CADHERIN; CD31 ANTIGEN; IMIDAZOLE DERIVATIVE; LEUKOCYTE ANTIGEN; VASCULAR ENDOTHELIAL CADHERIN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2, HUMAN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND ANTIGEN; VON WILLEBRAND FACTOR; ZOLEDRONIC ACID;

ARTICLE; BONE DEVELOPMENT; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SHAPE; CO-CULTURED CELLS; COCULTURE; CYTOLOGY; DRUG EFFECT; ENDOTHELIAL GENE EXPRESSION; ENDOTHELIUM CELL; GENE EXPRESSION; GENETICS; HUMAN; HUMAN DERMAL MICROVASCULAR ENDOTHELIAL CELLS (HDMEC); HUMAN MESENCHYMAL STEM CELLS (HMSC); MESENCHYMAL STROMA CELL; METABOLISM; MICROVASCULATURE; OSTEOBLAST; OSTEOGENIC GENE EXPRESSION; VASCULAR ENDOTHELIUM;

ALENDRONATE; CO-CULTURED CELLS; ENDOTHELIAL GENE EXPRESSION; HUMAN DERMAL MICROVASCULAR ENDOTHELIAL CELLS (HDMEC); HUMAN MESENCHYMAL STEM CELLS (HMSC); OSTEOGENIC GENE EXPRESSION; ZOLEDRONATE;

ALENDRONATE; ALKALINE PHOSPHATASE; ANTIGENS, CD; ANTIGENS, CD31; BONE DENSITY CONSERVATION AGENTS; CADHERINS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SHAPE; CELLS, CULTURED; COCULTURE TECHNIQUES; DIPHOSPHONATES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; HUMANS; IMIDAZOLES; MESENCHYMAL STROMAL CELLS; MICROVESSELS; OSTEOBLASTS; OSTEOGENESIS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VON WILLEBRAND FACTOR;

EID: 84891373536     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12154     Document Type: Article

References (63)

1. Russell R, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19: 733-59.
2. Russell RG. Bisphosphonates: the first 40 years. Bone. 2011; 49: 2-19.
3. Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone. 2011; 49: 50-5.
4. Allen MR, Burr DB. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone. 2011; 49: 56-65.
5. Willkinson MJ, Little GL. Bisphosphonates in orthopedic applications. Bone. 2011; 49: 95-102.
6. Pan B, To LB, Farrugia AN, et al. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone. 2004; 34: 112-23.
7. Knoch F, Jaquiery C, Kowalsky M. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials. 2005; 26: 6941-9.
8. Duque G, Rivas D. Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res. 2007; 22: 1603-11.
9. Koch FP, Merkel C, Al-Nawas B, et al. Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner - A quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2. J Craniomaxillofac Surg. 2011; 39: 562-9.
10. Ohe J-Y, Kwon Y-D, Lee H-W. Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts. Clin Oral Invest. 2012; 16: 1153-9.
11. Koch FP, Merkel C, Ziebart T, et al. Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro. Clin Oral Invest. 2012; 16: 79-86.
12. Greiner S, Kadow-Romacker A, Lubberstedt M, et al. The effect of zoledronic acid incorporated in a poly(D, L-lactide) implant coating on osteoblasts in vitro. J Biomed Mater Res A. 2007; 80: 769-75.
13. Boanini E, Torricelli P, Gazzano M, et al. Alendronate-hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells. Biomaterials. 2008; 29: 790-6.
14. Panzavolta S, Torricelli P, Bracci B, et al. Alendronate and Pamidronate calcium phosphate bone cements: setting properties and in vitro response of osteoblast and osteoclast cells. J Inorg Biochem. 2009; 103: 101-6.
15. Tatli U, Stün YU, Kürkçü M, et al. Effects of zoledronic acid on healing of mandibular fractures: an experimental study in rabbits. J Oral Maxillofac Surg. 2011; 69: 1726-35.
16. Agholme F, Andersson T, Tengvall P, et al. Local bisphosphonate release versus hydroxyapatite coatings for stainless stell screw fixation in rat tibiae. J Mat Sci. 2012; 23: 743-52.
17. Pampu AA, Dolanmaz D, Tuz HH, et al. Experimental evaluation of the effects of zoledronic acid on regenerate bone formation and osteoporosis in mandibular distraction osteogenesis. J Oral Maxillofac Surg. 2006; 64: 1232-6.
18. Stadelmann VA, Gauthier O, Terrier A, et al. Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study. Eur Cell Mater. 2008; 16: 10-6.
19. Verron E, Gauthier O, Janvier P, et al. In vivo bone augmentation in an osteoporotic environment using bisphosphonate-loaded calcium deficient apatite. Biomaterials. 2010; 31: 7776-84.
20. Qi M, Hu J, Li J, et al. Effect of Zoledronate acid treatment on osseointegration and fixation of implants in autologous iliac bone grafts in ovariectomized rabbits. Bone. 2012; 50: 119-27.
21. Clézardin P, Benzaïd I, Croucher PI. Bisphosphonates in preclinical bone oncology. Bone. 2011; 49: 66-70.
22. Sarasquete ME, Gonzalez M, San Miguel JF, et al. Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis. 2009; 15: 382-7.
23. Yarom N, Yahalom R, Shoshani Y, et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int. 2007; 18: 1363-70.
24. Yamada J, Tsuno NH, Kitayama J, et al. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res. 2009; 151: 115-20.
25. Ziebart T, Pabst A, Klein MO, et al. Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig. 2011; 15: 105-11.
26. Hashimoto K, Morishige K, Sawada K, et al. Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem Biophys Res Commun. 2007; 354: 478-84.
27. Michailidou M, Brown HK, Lefley DV, et al. Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel? J Vasc Res. 2010; 47: 481-93.
28. Scavelli C, Pietro G, Cirulli T, et al. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther. 2007; 6: 3256-62.
29. Villars F, Bordenave L, Bareille R, et al. Effect of human endothelial cells on human bone marrow stromal cell phenotype: role of VEGF? J Cell Biochem. 2000; 79: 672-85.
30. Villars F, Guillotin B, Amedee T, et al. Effect of HUVEC on human osteoprogenitor cell differentiation needs heterotypic gap junction communication. Am J Physiol Cell Physiol. 2002; 282: C775-85.
31. Stahl A, Wenger A, Webe H, et al. Bi-directional cell contact-dependent regulation of gene expression between endothelial cells and osteoblasts in a three-dimensional spheroidal coculture model. Biochem Biophys Res Commun. 2004; 322: 684-92.
32. Guillotin B, Bareille R, Bourget C, et al. Interaction between human umbilical vein endothelial cells and human osteoprogenitors triggers pleitropic effect that may support osteoblastic function. Bone. 2008; 42: 1080-91.
33. Aguirre A, Planell JA, Engel E. Dynamics of bone marrow-derived endothelial progenitor cell/mesenchymal stem cell interaction in co-culture and its implications in angiogenesis. Biochem Biophys Res Commun. 2010; 400: 284-91.
34. Saleh F, Whyte M, Genever P. Effects of endothelial cells on human mesenchymal stem cells activity in a three-dimensional in vitro model. Eur Cells Mater. 2011; 22: 242-57.
35. Laranjeira M, Fernandes MH, Monteiro FJ. Reciprocal induction of human dermal microvascular endothelial cells and human mesenchymal stem cells: time-dependent profile in a co-culture system. Cell Prolif. 2012; 45: 320-34.
36. Kanczler JM, Oreffo ROC. Osteogenesis and angiogenesis: the potential for engineering bone. Eur Cells Mater. 2008; 15: 100-14.
37. Unger RE, Sartoris A, Peters K, et al. Tissue-like self-assembly in cocultures of endothelial cells and osteoblasts and the formation of microcapillary-like structures on three-dimensional porous biomaterials. Biomaterials. 2007; 28: 3965-76.
38. Hofmann A, Ritz U, Verrier S, et al. The effect of human osteoblasts on proliferation and neo-vessel formation of human umbilical vein endothelial cells in a long-term 3D co-culture on polyurethane scaffolds. Biomaterials. 2008; 29: 4217-26.
39. Skerjanec A, Berenson J, Hsu C, et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol. 2003; 43: 154-62.
40. Scheper MA, Badros A, Salama AR, et al. A novel bioassay model to determine clinically significant bisphosphonate levels. Support Care Cancer. 2009; 17: 1553-7.
41. Cremers S, Papapoulos S. Pharmacology of bisphosphonates. Bone. 2011; 49: 42-9.
42. Yamashita J, Koi K, Yang DY, et al. Effect of Zoledronate on oral wound healing in rats. Clin Cancer Res. 2011; 17: 1405-14.
43. Tsai S-H, Huang P-H, Chang W-C, et al. Zoledronate inhibits ischemia-induced neovascularization by impairing the mobilization and function of endothelial progenitor cells. PLoS ONE. 2012; 7: 241065.
44. Aubin J. Mesenchymal stem cell and osteoblast differentiation. In: Bilezikian JP, Raisz LG, Martin TJ, editors. Principles of bone biology. San Diego: Academic Press; 2008. pp. 85-107.
45. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007; 9: S1.
46. Mathov I, Plotkin LI, Sgarlata CL, et al. Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro. J Bone Miner Res. 2001; 16: 2050-6.
47. Jun JH, Yoon W-J, Seo S-B, et al. BMP2-activated Erk/MAP kinase stabilizes Runx2 by increasing p300 levels and histone acetyltransferase activity. J Biol Chem. 2010; 285: 36410-9.
48. Giuliani N, Girasole G, Pedrazzoni M, et al. Alendronate stimulates β-FGF production and mineralized nodule formation in human osteoblastic cells and osteoblastogenesis in human bone marrow cultures. J Bone Miner Res. 1995; 10: S171.
49. Kotev-Emeth S, Savion N, Pri-chen S, et al. Effect of maturation on the osteogenic response of cultured stromal bone marrow cells to basic fibroblast growth factor. Bone. 2000; 27: 777-83.
50. Hughes-Fulford M, Li CF. The role of FGF-2 and BMP-2 in regulation of gene induction, cell proliferation and mineralization. J Orthop Surg Res. 2011; 6: 8.
51. Raucci A, Bellosta P, Grassi R, et al. Osteoblast proliferation or differentiation is regulated by relative strengths of opposing signaling pathways. J Cell Physiol. 2008; 215: 442-51.
52. Xue Y, Xing Z, Hellem S, et al. Endothelial cells influence the osteogenic potential of bone marrow stromal cells. Biomed Eng Online. 2009; 17: 34.
53. Xue Y, Xing Z, Bolstad AI, et al. Co-culture of human bone marrow stromal cells with endothelial cells alters gene expression profiles. Int J Artif Organs. 2013. doi: 10.5301/ijao.5000229.
54. Torbjorn TO, Blois AL, Xue Y, et al. Osteogenic stimulatory conditions enhance growth and maturation of endothelial cell microvascular networks in culture with mesenchymal stem cells. J Tissue Eng. 2012; 3: 2041731412443236.
55. Sven H, Lampert FM, Orimo H, et al. Up-regulation of alkaline phosphatase expression in human primary osteoblasts by cocultivation with primary endothelial cells is mediated by p38 mitogen-activated protein kinase-dependent mRNA stabilization. Tissue Eng Part A. 2009; 15: 3437-47.
56. Richard RP, Richardson CD, Sato TN. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci USA. 2002; 99: 8219-24.
57. Gerber HP, Vu TH, Ryan AM, et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 1999; 5: 623-8.
58. Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol. 2006; 290: H547-59.
59. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006; 290: H560-76.
60. Kimura M, Miyazawa K, Tabuchi M, et al. Bisphosphonate treatment increases the size of the mandibular condyle and normalizes growth of the mandibular ramus in osteoprotegerin-deficient mice. Calcif Tissue Int. 2008; 82: 137-47.
61. Martini G, Gennari L, Merlotti D, et al. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone. 2007; 40: 457-63.
62. Soki FN, Li X, Berry J, et al. The effects of zoledronic acid in the bone and vasculature support of hematopoietic stem cell niches. J Cell Biochem. 2013; 114: 67-78.
63. Roux C. Potential effects of bisphosphonates on bone ultrastructure. Osteoporos Int. 2009; 20: 1093-5.